BridgeBio (BBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting commenced as an interactive webcast, following corporate bylaws and Delaware law.
Stockholders and guests were welcomed, and the agenda included reviewing and voting on proposals outlined in the proxy statement.
Voting procedures and rules of conduct were explained, with polls open during the meeting.
Board and executive committee updates
Directors and officers present were introduced, including the CEO, CFO, and other key executives.
Representatives from Deloitte (auditors), Goodwin Procter (outside counsel), and American Election Services (inspector of elections) attended.
Shareholder proposals
Five proposals were presented: election of three directors, advisory vote on executive compensation, advisory vote on frequency of compensation votes, ratification of Deloitte as auditor, and amendment to the stock option plan.
Board recommended approval of all proposals.
Latest events from BridgeBio
- Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches.BBIO
Jefferies Global Healthcare Conference 20264 Jun 2026 - Late-stage pipeline and strong cash position drive multiple launches in rare genetic diseases.BBIO
Corporate presentation4 Jun 2026 - Attruby’s market leadership and a robust pipeline position the company for multi-billion dollar peak sales.BBIO
Bank of America Global Healthcare Conference 202614 May 2026 - Q1 2026 revenue hit $194.5M, driven by Attruby growth and a $500M buyback program launch.BBIO
Q1 20268 May 2026 - Multiple late-stage rare disease programs and strong financials drive upcoming launches.BBIO
Corporate presentation7 May 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and stock plan expansion.BBIO
Proxy filing24 Apr 2026 - Annual meeting covers director elections, executive pay, auditor ratification, and stock plan amendment.BBIO
Proxy filing24 Apr 2026 - Multiple late-stage therapies for genetic diseases are nearing approval, driving strong growth.BBIO
Corporate presentation24 Mar 2026 - Strong late-stage pipeline and efficient commercial strategy drive growth outlook.BBIO
Barclays 28th Annual Global Healthcare Conference11 Mar 2026